quinazolines has been researched along with thalidomide in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Cervantes, F | 2 |
| Goldman, B | 1 |
| Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
| Silver, R | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Chon, HS; Hu, W; Kavanagh, JJ | 1 |
| Curtiss, FR | 1 |
| Horn, L; Sandler, AB | 1 |
| Aragon-Ching, JB; Dahut, WL | 1 |
| Dhalluin, X; Scherpereel, A | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Cao, KI; Kirova, YM | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Miyamoto, T; Yoshimoto, G | 1 |
| Chaplain, MAJ; Hill, L; Kapelyukh, Y; Wolf, R | 1 |
| Thieblemont, C | 1 |
| Bao, Y; Chen, Q; Liu, L; Sun, X; Wang, Y; Xu, Y | 1 |
| Bissonnette, R; Boguniewicz, M; Guttman-Yassky, E; Hanifin, JM; Kilty, I; Purohit, V; Tallman, AM; Wollenberg, A; Zielinski, MA | 1 |
| Bradner, J; Briggs, KJ; Buhrlage, SJ; Dasilva, E; Doench, JG; Donovan, KA; Duplaquet, L; Endress, JE; Fischer, ES; Gray, NS; Gygi, SP; Harris, IS; Ishoey, M; Kaelin, WG; Koduri, V; Lampson, BL; Liu, X; Medin, JA; Oser, MG; Ott, CJ; Paulk, J; Paulo, JA; Sabet, AH; Teng, M; Wang, AC; Zhang, T | 1 |
17 review(s) available for quinazolines and thalidomide
| Article | Year |
|---|---|
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Topics: Aged; Anemia; Aneuploidy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Case Management; Combined Modality Therapy; Female; Hemoglobins; Humans; Hydroxyurea; Karyotyping; Male; Middle Aged; Palliative Care; Primary Myelofibrosis; Prognosis; Quinazolines; Risk; Severity of Illness Index; Splenectomy; Survival Analysis; Thalidomide | 2001 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
Targeted therapies in gynecologic cancers.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Transfer Techniques; Genital Neoplasms, Female; Humans; Neovascularization, Pathologic; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thalidomide; Thionucleotides; Trastuzumab | 2006 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide | 2007 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Quinazolines; Signal Transduction; Sorafenib; Thalidomide; Vascular Endothelial Growth Factors | 2009 |
Chemotherapy and radiotherapy for mesothelioma.
Topics: Antineoplastic Agents; Asbestos; Combined Modality Therapy; Gefitinib; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mesothelioma; Pleural Neoplasms; Quinazolines; Ribonucleases; Thalidomide | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential | 2014 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Topics: Acetamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dermatitis, Atopic; Drug Approval; Humans; Immune System; Inflammation; Phosphodiesterase Inhibitors; Phthalic Acids; Pyridines; Quinazolines; Risk; Skin; Thalidomide | 2019 |
7 other study(ies) available for quinazolines and thalidomide
| Article | Year |
|---|---|
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous | 2005 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
The usage of a three-compartment model to investigate the metabolic differences between hepatic reductase null and wild-type mice.
Topics: Angiogenesis Inhibitors; Animals; Cytochrome P-450 Enzyme System; Disease Models, Animal; GABA Modulators; Gefitinib; Liver; Mice; Mice, Transgenic; Midazolam; Models, Biological; NADPH-Ferrihemoprotein Reductase; Protein Kinase Inhibitors; Quinazolines; Thalidomide | 2017 |
Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Targeting oncoproteins with a positive selection assay for protein degraders.
Topics: Adaptor Proteins, Signal Transducing; Basic Helix-Loop-Helix Transcription Factors; Benzylamines; CRISPR-Cas Systems; Humans; Ikaros Transcription Factor; Oncogene Proteins; Proteolysis; Quinazolines; Thalidomide; Transcription Factors | 2021 |